A Phase 2 interventional study of Lenvatinib and Paclitaxel in Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma and Platinum-Resistant Primary Peritoneal Carcinoma, sponsored by Floor Backes, MD. Active, not recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Floor Backes, MD · Phase 2, Interventional, and Treatment
How we know · 7 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing lenvatinib in Endometrial Neoplasms — 4 open to participants now, 6 under way, none of them phase 3. lenvatinib · Endometrial Neoplasms.
Among the 15 studies testing lenvatinib in Endometrial Neoplasms, this one is the 7th largest by enrollment, is the only one that started in 2021, is one of 6 in phase 2, and was the 8th registered.
1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.
Browse Endometrial Neoplasms studies →4 of the 15 studies testing lenvatinib in Endometrial Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18+ · Women only
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Aaron Wolfson · Sites in United States
Ages 18+ · Women only
University Medical Center Groningen · Sites in Netherlands
Ages 65+
By country, each count listing its studies:
lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, lenvatinib is the treatment under test here. Read study by study →
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 3 · Phase 4 1
First in 2010; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 38 is below the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 32 across the 15 interventional studies. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 15 have an industry lead sponsor. The 10 most frequent:
Floor Backes, MD is the lead sponsor of 2 studies on the registry; none are open to participants now.
Floor Backes, MD has 2 studies filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies testing lenvatinib in Endometrial Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06253494National Cancer Institute (NCI)Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies testing lenvatinib in Endometrial Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This phase II clinical trial studies the effect of lenvatinib, pembrolizumab, and paclitaxel in treating patients with endometrial, epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). While all 3 study drugs are FDA approved, and 2-drug combinations have been studied, the 3- drug combination has not been studied yet. The investigators believe that the addition of pembrolizumab to weekly paclitaxel and lenvatinib (or weekly paclitaxel to pembrolizumab and lenvatinib) is highly effective and safe with manageable side effects in both recurrent endometrial and platinum resistant ovarian cancer. The purpose of this trial is to study how well lenvatinib, pembrolizumab, and weekly paclitaxel work together in women who have recurrent endometrial cancer and/or recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer, and what kind of side effects patients may experience.
PRIMARY OBJECTIVE:
I. To determine objective antitumor activity (complete and partial response) of lenvatinib, pembrolizumab, and weekly paclitaxel as measured by Response Evaluation Criteria in Solid Tumors (RECIST) criteria in recurrent endometrial and platinum resistant ovarian cancer.
SECONDARY OBJECTIVES:
I. To determine the safety and tolerability weekly paclitaxel, lenvatinib, and pembrolizumab in study patients.
II. To measure the progression free survival in the study population. III. To measure the overall survival in the study population.
EXPLORATORY OBJECTIVE:
I. To explore the baseline tumor genetic and microenvironment parameters predictive of clinical benefit or resistance to the treatment combination and potential mechanisms of resistance.
OUTLINE:
Beginning cycle 1 day 1, patients receive lenvatinib PO daily, pembrolizumab IV on day 1, and paclitaxel IV over 1 hour on days 1, 8, and 15, on a 21 day cycle in the absence of disease progression or unacceptable toxicity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
>= 9.0 g/dL or >= 5.6 mmol/L (within 10 days prior to the start of study treatment)
Creatinine =\< 1.5 x (ULN) OR measured or calculated ( [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 30 mL/min for participant with creatinine levels > 1.5 x institutional ULN (within 10 days prior to the start of study treatment)
Exclusion Criteria:
Significant arterial or venous thromboembolic disease or vascular disorders within 6 months prior to administration of first dose of study drug, including by not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive paclitaxel IV over 1 hour on days -15 and -8 and lenvatinib PO QD on days -15 to 0. Beginning cycle 1 day 1, patients receive lenvatinib PO QD, pembrolizumab IV over 30 minutes on day 1, and paclitaxel IV over 1 hour on days 1, 8, and 15. Cycles with pembrolizumab repeats every 3 weeks for up to 2 years, and cycles with paclitaxel and lenvatinib repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
Drug: Lenvatinib · Drug: Paclitaxel · Biological: Pembrolizumab
Given PO
Also known as: E7080, ER-203492-00, Multi-Kinase Inhibitor E7080
Given IV
Also known as: Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
Given IV
Also known as: Keytruda, Lambrolizumab, MK-3475, SCH 900475
Objective Tumor Response
Will be assessed by Response Evaluation Criteria in Solid Tumors 1.1. Will be reported as a percentage and will be calculated by the number of patients with a complete or partial response divided by the total number of patients. The percentage of patients with stable disease and progressive disease will be calculated in a similar fashion.
Time frame: through study completion, an average of 1 year
Safety and Toxicity
Toxicity as assessed by Common Terminology for Adverse Events version 5.0 will be evaluated descriptively using frequencies and percentages and will be reported using tables. All patients who receive treatment, regardless of eligibility, will be evaluated for toxicity. Toxicities by type and maximum grade over the course of treatment and follow up will be summarized and by date of occurrence.
Time frame: through study completion, an average of 1 year
Progression Free Survival
Time from first therapy to the time of cancer progression, death or lost to follow up.
Time frame: through study completion, an average of 1 year
| Milestone | Safety Lead in: Dose Level 1 | Safety Lead in: Dose Level -1 | Phase 2 (Dose Level -1) |
|---|---|---|---|
| Started | 4 | 0 | 0 |
| Completed | 4 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Safety Lead in: Dose Level 1 | Safety Lead in: Dose Level -1 | Phase 2 (Dose Level -1) |
|---|---|---|---|
| Started | 0 | 5 | 0 |
| Completed | 0 | 5 | 0 |
| Not completed | 0 | 0 | 0 |
| Milestone | Safety Lead in: Dose Level 1 | Safety Lead in: Dose Level -1 | Phase 2 (Dose Level -1) |
|---|---|---|---|
| Started | 0 | 0 | 29 |
| Completed | 0 | 0 | 29 |
| Not completed | 0 | 0 | 0 |
Will be assessed by Response Evaluation Criteria in Solid Tumors 1.1. Will be reported as a percentage and will be calculated by the number of patients with a complete or partial response divided by the total number of patients. The percentage of patients with stable disease and progressive disease will be calculated in a similar fashion.
| Participants | Safety Lead in: Dose Level 1 | Safety Lead in: Dose Level -1 | Phase 2 (Dose Level -1) |
|---|---|---|---|
| Complete Response | 0 | 0 | 3 |
| Not assessed | 0 | 0 | 3 |
| Not evaluable | 2 | 0 | 2 |
| Partial Response | 1 | 2 | 12 |
| Progressive Disease | 0 | 0 | 2 |
| Stable Disease | 1 | 3 | 7 |
Toxicity as assessed by Common Terminology for Adverse Events version 5.0 will be evaluated descriptively using frequencies and percentages and will be reported using tables. All patients who receive treatment, regardless of eligibility, will be evaluated for toxicity. Toxicities by type and maximum grade over the course of treatment and follow up will be summarized and by date of occurrence.
| participants | Safety Lead in: Dose Level 1 | Safety Lead in: Dose Level -1 | Phase 2: Dose Level -1 |
|---|---|---|---|
| Anemia | 2 | 4 | 23 |
| Febrile neutropenia | 0 | 0 | 2 |
| Myocardial infarction | 0 | 0 | 1 |
| Palpitations | 0 | 0 | 3 |
| Sinus tachycardia | 0 | 2 | 7 |
| Ear pain | 0 | 0 | 2 |
| Tinnitus | 0 | 0 | 4 |
| Hyperthyroidism | 0 | 0 | 2 |
| Hypothyroidism | 3 | 4 | 16 |
| Blurred vision | 0 | 0 | 6 |
| Dry eye | 1 | 1 | 3 |
| Eye disorders - other | 0 | 1 | 3 |
| Photophobia | 0 | 0 | 1 |
| Watering eyes | 0 | 1 | 2 |
| Abdominal distension | 1 | 2 | 3 |
| Abdominal pain | 1 | 2 | 15 |
| Bloating | 1 | 0 | 5 |
| Colitis | 0 | 0 | 1 |
| Constipation | 2 | 2 | 12 |
| Eosinophilia | 0 | 0 | 1 |
| Aortic valve disease | 0 | 0 | 1 |
| Atrial fibrillation | 0 | 0 | 1 |
| Atrioventricular block first degree | 0 | 0 | 1 |
| Cardiac disorders - Other | 0 | 0 | 2 |
| Hearing impaired | 0 | 0 | 1 |
| Vertigo | 0 | 0 | 1 |
| Cataract | 0 | 0 | 1 |
| Glaucoma | 0 | 0 | 1 |
| Anal fistula | 0 | 0 | 1 |
| Ascites | 0 | 0 | 1 |
| Belching | 0 | 0 | 1 |
| Diarrhea | 2 | 3 | 23 |
| Dry Mouth | 3 | 1 | 11 |
| Dyspepsia | 1 | 2 | 5 |
| Dysphagia | 1 | 1 | 2 |
| Fecal incontinence | 0 | 1 | 3 |
| Flatulence | 0 | 0 | 4 |
| Gastroesophageal reflux disease | 0 | 1 | 5 |
| Gastrointestinal disorders - Other | 0 | 0 | 3 |
| Hemorrhoids | 0 | 0 | 2 |
| Ileus | 0 | 0 | 2 |
| Lip pain | 0 | 0 | 1 |
| Mucositis oral | 2 | 4 | 20 |
| Nausea | 3 | 4 | 21 |
| Oral dysesthesia | 0 | 0 | 2 |
| Oral pain | 0 | 0 | 7 |
| Rectal hemorrhage | 0 | 0 | 6 |
| Rectal pain | 0 | 0 | 3 |
| Small intestinal obstruction | 0 | 0 | 1 |
| Vomiting | 2 | 3 | 19 |
| Chills | 1 | 0 | 10 |
| Edema face | 0 | 1 | 3 |
| Edema limbs | 0 | 1 | 14 |
| Fatigue | 4 | 4 | 25 |
| Fever | 0 | 0 | 5 |
| General disorders and administration site conditions - Other | 0 | 1 | 1 |
| Generalized edema | 1 | 0 | 1 |
| Infusion site extravasation | 0 | 0 | 1 |
| Localized edema | 0 | 1 | 2 |
| Malaise | 0 | 0 | 1 |
| Non-cardiac chest pain | 1 | 1 | 7 |
| Pain | 0 | 0 | 3 |
| Bile duct stenosis | 0 | 0 | 1 |
| Cholecystitis | 0 | 0 | 1 |
| Allergic reaction | 0 | 1 | 2 |
| Anorectal infection | 0 | 0 | 1 |
| Conjunctivis | 0 | 0 | 1 |
| Device related infection | 0 | 0 | 2 |
| Enterocolitis infectious | 0 | 0 | 2 |
| Folliculitis | 0 | 0 | 1 |
| Infections and infestations - Other | 0 | 2 | 3 |
| Lung infection | 0 | 0 | 5 |
| Mucosal infection | 0 | 0 | 1 |
| Nail infection | 0 | 1 | 3 |
| Rash pustular | 1 | 0 | 2 |
| Sinusitis | 0 | 0 | 2 |
| Skin infection | 0 | 0 | 1 |
| Thrush | 0 | 0 | 2 |
| Tooth infection | 0 | 0 | 1 |
| Upper Respiratory Infection | 1 | 0 | 4 |
| Urinary tract infection | 1 | 3 | 9 |
| Vaginal infection | 0 | 1 | 3 |
| Bruising | 0 | 0 | 4 |
| Fall | 2 | 0 | 5 |
| Fracture | 0 | 0 | 1 |
| Infusion related reaction | 1 | 0 | 2 |
| Injury, poisoning and procedural complications - Other | 0 | 0 | 1 |
| Intestinal stoma site bleeding | 0 | 0 | 1 |
| Vascular access complication | 0 | 0 | 1 |
| Wound complication | 0 | 1 | 1 |
| Activated partial thromboplastine time prolonged | 0 | 1 | 6 |
| Alanine aminotransferase increased | 0 | 1 | 5 |
| Alkaline phosphatase increased | 0 | 1 | 5 |
| Aspartate aminotransferase increased | 0 | 1 | 7 |
| Blood bicarbonate decreased | 0 | 0 | 1 |
| Blood bilirubin increased | 0 | 0 | 3 |
| Blood lactate dehydrogenase increased | 0 | 2 | 6 |
| Cardiac troponin I increased | 0 | 0 | 3 |
| Cholesterol high | 0 | 0 | 1 |
| Creatinine increased | 1 | 1 | 4 |
| Electrocardiogram QT corrected interval prolonged | 0 | 1 | 2 |
| INR increased | 0 | 0 | 1 |
| Lipase increased | 0 | 0 | 1 |
| Lymphocyte count decreased | 1 | 3 | 22 |
| Lymphocyte count increased | 0 | 0 | 1 |
| Neutrophil count decreased | 1 | 5 | 19 |
| Pancreatic enzymes decreased | 0 | 0 | 1 |
| Platelet count decreased | 0 | 1 | 13 |
| Thyroid stimulating hormone increased | 1 | 1 | 7 |
| Weight gain | 0 | 1 | 5 |
| Weight loss | 4 | 3 | 15 |
| White blood cell decreased | 1 | 5 | 22 |
| Anorexia | 3 | 4 | 20 |
| Dehydration | 1 | 2 | 7 |
| Hyperglycemia | 1 | 5 | 17 |
| Hypercalcemia | 0 | 0 | 1 |
| Hyperkalemia | 0 | 0 | 2 |
| Hypernatremia | 0 | 0 | 1 |
| Hyperphosphatemia | 0 | 2 | 5 |
| Hypertriglyceridemia | 0 | 1 | 2 |
| Hyperuricemia | 0 | 1 | 5 |
| Hypoalbuminemia | 0 | 2 | 10 |
| Hypocalcemia | 0 | 2 | 6 |
| Hypoglycemia | 0 | 1 | 2 |
| Hypokalemia | 1 | 2 | 14 |
| Hypomagnesemia | 0 | 2 | 9 |
| Hyponatremia | 2 | 3 | 14 |
| Hypophosphatemia | 0 | 0 | 4 |
| Paroxysmal atrial tachycardia | 1 | 1 | 0 |
| Hemorrhoidal hemorrhage | 1 | 0 | 0 |
| Back pain | 3 | 1 | 7 |
| Flank pain | 1 | 0 | 1 |
| Myalgia | 3 | 0 | 5 |
| Neck pain | 1 | 0 | 5 |
| Pain in extremity | 3 | 1 | 6 |
| Headache | 1 | 2 | 21 |
| Peripheral sensory neuropathy | 1 | 0 | 9 |
| Depression | 1 | 2 | 10 |
| Insomnia | 1 | 1 | 8 |
| Dysuria | 1 | 1 | 10 |
| Proteinuria | 1 | 3 | 17 |
| Urinary frequency | 1 | 1 | 6 |
| Urinary incontinence | 1 | 1 | 3 |
| Urinary retention | 1 | 0 | 3 |
| Urinary tract obstruction | 1 | 1 | 1 |
| Cough | 1 | 2 | 16 |
| Dyspnea | 1 | 4 | 22 |
| Epistaxis | 1 | 2 | 19 |
| Hoarseness | 1 | 2 | 6 |
| Hypoxia | 1 | 1 | 5 |
| Nasal congestion | 1 | 1 | 14 |
| Postnasal drip | 1 | 0 | 6 |
| Productive cough | 1 | 2 | 0 |
| Sore throat | 1 | 1 | 13 |
| Alopecia | 1 | 2 | 2 |
| Rash acneiform | 1 | 0 | 2 |
| Rash maculo-papular | 1 | 3 | 17 |
| Surgical and medical procedures - Other | 1 | 1 | 0 |
| Hypertension | 1 | 2 | 24 |
| Hypotension | 1 | 1 | 9 |
| Ear and labyrinth disorders - Other | 0 | 1 | 0 |
| Esophageal stenosis | 0 | 1 | 0 |
| Esophagitis | 0 | 1 | 0 |
| Hypothermia | 0 | 1 | 0 |
| Arthralgia | 0 | 1 | 5 |
| Dizziness | 0 | 2 | 14 |
| Dysgeusia | 0 | 2 | 10 |
| Extrapyramidal disorder | 0 | 1 | 0 |
| Anxiety | 0 | 1 | 4 |
| Cystitis noninfective | 0 | 1 | 0 |
| Glucosuria | 0 | 1 | 2 |
| Hematuria | 0 | 2 | 13 |
| Vaginal discharge | 0 | 1 | 2 |
| Vaginal inflammation | 0 | 1 | 0 |
| Respiratory, thoracic and mediastinal disorders - Other | 0 | 1 | 1 |
| Nail changes | 0 | 1 | 7 |
| Palmar-plantar erythrodysesthesia syndrome | 0 | 2 | 8 |
| Skin and subcutaneous tissue disorders - Other | 0 | 2 | 5 |
| Skin ulceration | 0 | 1 | 1 |
| Flushing | 0 | 2 | 4 |
| Bone pain | 0 | 0 | 2 |
| Generalized muscle weakness | 0 | 0 | 6 |
| Joint range of motion decreased | 0 | 0 | 1 |
| Muscle cramp | 0 | 0 | 8 |
| Muscle weakness lower limb | 0 | 0 | 2 |
| Musculoskeletal and connective tissue disorder - Other, specify | 0 | 0 | 1 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other | 0 | 0 | 1 |
| Concentration impairment | 0 | 0 | 1 |
| Edema cerebral | 0 | 0 | 1 |
| Memory impairment | 0 | 0 | 1 |
| Nervous system disorders - Other | 0 | 0 | 1 |
| Peripheral motor neuropathy | 0 | 0 | 1 |
| Presyncope | 0 | 0 | 1 |
| Stroke | 0 | 0 | 1 |
| Syncope | 0 | 0 | 2 |
| Tremor | 0 | 0 | 3 |
| Vasovagal reaction | 0 | 0 | 1 |
| Agitation | 0 | 0 | 2 |
| Confusion | 0 | 0 | 1 |
| Hallucinations | 0 | 0 | 2 |
| Psychiatric disorders - Other | 0 | 0 | 1 |
| Restlessness | 0 | 0 | 4 |
| Acute kidney injury | 0 | 0 | 2 |
| Bladder spasm | 0 | 0 | 1 |
| Chronic kidney disease | 0 | 0 | 1 |
| Renal and urinary disorders - Other | 0 | 0 | 1 |
| Urinary urgency | 0 | 0 | 4 |
| Urine discoloration | 0 | 0 | 1 |
| Pelvic floor muscle weakness | 0 | 0 | 1 |
| Pelvic pain | 0 | 0 | 9 |
| Vaginal fistula | 0 | 0 | 1 |
| Vaginal hemorrhage | 0 | 0 | 2 |
| Vaginal pain | 0 | 0 | 2 |
| Allergic rhinitis | 0 | 0 | 1 |
| Pharyngeal mucositis | 0 | 0 | 1 |
| Pleural effusion | 0 | 0 | 2 |
| Pneumonitis | 0 | 0 | 2 |
| Rhinorrhea | 0 | 0 | 3 |
| Sinus pain | 0 | 0 | 1 |
| Voice alteration | 0 | 0 | 2 |
| Wheezing | 0 | 0 | 1 |
| Dry skin | 0 | 0 | 3 |
| Hyperhidrosis | 0 | 0 | 2 |
| Nail discoloration | 0 | 0 | 1 |
| Pain of skin | 0 | 0 | 1 |
| Pruritus | 0 | 0 | 7 |
| Hot flashes | 0 | 0 | 2 |
| Thromboembolic event | 0 | 0 | 5 |
Time from first therapy to the time of cancer progression, death or lost to follow up.
| months | Safety Lead in: Dose Level 1 | Safety Lead in: Dose Level -1 | Phase 2 (Dose Level -1) |
|---|---|---|---|
| Progression Free Survival | 5.15 (4.20 to NA) | 7.2 (3.0 to NA) | 6.80 (3.90 to 15.10) |
Collected over Adverse event data was collected through treatment completion plus 90 days, an average of 1 year. All-cause mortality data is collected as part of long-term follow-up until participant death, withdrawal of consent, or until the study closes, with an average follow-up of15.6 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Lead in: Dose Level 1 | 4/4 (100%) | 3/4 (75%) | 4/4 (100%) |
| Safety Lead in: Dose Level -1 | 5/5 (100%) | 4/5 (80%) | 5/5 (100%) |
| Phase 2 (Dose Level -1) | 22/29 (75.9%) | 19/29 (65.5%) | 29/29 (100%) |
| Event | Safety Lead in: Dose Level 1 | Safety Lead in: Dose Level -1 | Phase 2 (Dose Level -1) |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 0/4 | 2/5 | 1/29 |
| AnemiaBlood and lymphatic system disorders | 1/4 | 0/5 | 1/29 |
| FatigueGeneral disorders and administration site conditions | 1/4 | 0/5 | 1/29 |
| AnorexiaMetabolism and nutrition disorders | 1/4 | 0/5 | 1/29 |
| DehydrationMetabolism and nutrition disorders | 1/4 | 0/5 | 1/29 |
| HyponatremiaMetabolism and nutrition disorders | 1/4 | 0/5 | 1/29 |
| HypokalemiaMetabolism and nutrition disorders | 1/4 | 0/5 | 0/29 |
| Urinary tract obstructionRenal and urinary disorders | 1/4 | 0/5 | 0/29 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/4 | 0/5 | 0/29 |
| DiarrheaGastrointestinal disorders | 0/4 | 1/5 | 3/29 |
| Event | Safety Lead in: Dose Level 1 | Safety Lead in: Dose Level -1 | Phase 2 (Dose Level -1) |
|---|---|---|---|
| FatigueGeneral disorders and administration site conditions | 4/4 | 4/5 | 25/29 |
| Neutrophil count decreasedInvestigations | 1/4 | 5/5 | 19/29 |
| Weight lossInvestigations | 4/4 | 3/5 | 15/29 |
| White blood cell decreasedInvestigations | 1/4 | 5/5 | 22/29 |
| HyperglycemiaMetabolism and nutrition disorders | 1/4 | 5/5 | 17/29 |
| AnemiaBlood and lymphatic system disorders | 2/4 | 4/5 | 23/29 |
| HypothyroidismEndocrine disorders | 3/4 | 4/5 | 16/29 |
| Mucositis oralGastrointestinal disorders | 2/4 | 4/5 | 20/29 |
| NauseaGastrointestinal disorders | 3/4 | 4/5 | 21/29 |
| AnorexiaMetabolism and nutrition disorders | 3/4 | 4/5 | 20/29 |
| Age, Continuous(years) | Safety Lead in: Dose Level 1 | Safety Lead in: Dose Level -1 | Phase 2 | Total |
|---|---|---|---|---|
| Median | 59 (45 to 68) | 65 (64 to 78) | 63 (37 to 78) | 64.5 (37 to 78) |
| Sex: Female, Male(Participants) | Safety Lead in: Dose Level 1 | Safety Lead in: Dose Level -1 | Phase 2 | Total |
|---|---|---|---|---|
| Female | 4 | 5 | 29 | 38 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Safety Lead in: Dose Level 1 | Safety Lead in: Dose Level -1 | Phase 2 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 | 2 |
| Not Hispanic or Latino | 3 | 5 | 28 | 36 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Safety Lead in: Dose Level 1 | Safety Lead in: Dose Level -1 | Phase 2 | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 1 |
| White | 2 | 5 | 25 | 32 |
| More than one race | 2 | 0 | 1 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Safety Lead in: Dose Level 1 | Safety Lead in: Dose Level -1 | Phase 2 | Total |
|---|---|---|---|---|
| United States | 4 | 5 | 29 | 38 |
| Primary site of cancer(Participants) | Safety Lead in: Dose Level 1 | Safety Lead in: Dose Level -1 | Phase 2 | Total |
|---|---|---|---|---|
| Ovarian Cancer | 3 | 3 | 20 | 26 |
| Endometrial Cancer | 1 | 2 | 9 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2021 to primary completion in Jul 2025, 46 months.
Results were first posted in Oct 2026, 1 year 3 months after primary completion.
Of 109 non-industry phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 115. This study's 46 months is below that.
Counting every sponsor, half of 141 studies reached it within 55 months; a quarter within 37 and three quarters within 115.
Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Mar 2027, on Oct 21, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenvatinib · Paclitaxel · Pembrolizumab
Floor Backes, MD